GS CA2
Alternative Names: GS-CA-2Latest Information Update: 28 Nov 2021
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections